LUMislim Compounded Tirzepatide

Tirzepatide is a once-weekly GLP-1 + GIP dual-agonist for medically supervised weight management. It activates two appetite-regulating hormones to reduce cravings, improve metabolism, and support sustained fat loss. LUMislim ships a compounded preparation prepared by a Philippine-licensed compounding pharmacy under your physician's order - the same active molecule used in branded tirzepatide products, prescribed at the dose your physician determines after reviewing your assessment.

Each LUMislim delivery ships discreetly and temperature-controlled, with everything you need for your weekly dose:

• Lyophilized peptide vial — your prescribed weekly dose
• Pharma-grade bacteriostatic (BAC) water — for reconstitution
• Insulin syringes — for weekly subcutaneous injection
• 3cc syringe — for reconstitution
• Alcohol swabs
• Instruction card — step-by-step guide

Care Team support included via Viber — message us anytime if you have questions during preparation or injection.

One subcutaneous injection per week — into the thigh, abdomen, or upper arm. Each LUMislim delivery includes pre-filled vials, sterile syringes, and easy-to-follow instructions. Your physician confirms your starting dose and titration schedule before your first supply is dispatched. Your Care Team checks in monthly via Viber.

Published clinical trials of branded tirzepatide (Jastreboff et al., SURMOUNT-1, NEJM 2022) at therapeutic doses report an average body weight reduction of 15–22% over 72 weeks. SURMOUNT-4 (Aronne et al., JAMA 2024) demonstrated that continued treatment maintained these losses. Compounded tirzepatide preparations contain the same active molecule but have not been studied in equivalent efficacy or maintenance trials. Individual results depend on dose, diet, sleep, and physical activity. Most patients notice meaningful changes within the first 8–12 weeks. Your Care Team adjusts your protocol based on your monthly check-ins.

Most patients experience mild gastrointestinal effects that typically subside within 2–4 weeks:

• Nausea
• Mild constipation or diarrhea
• Reduced appetite
• Fatigue (less common)
• Mild injection-site reactions

Stop your dose and message your physician immediately if you experience severe abdominal pain, persistent vomiting, signs of dehydration, or any allergic reaction. Before starting, tell your physician about any personal or family history of thyroid cancer, MEN-2 syndrome, pancreatitis, or severe gastrointestinal disease.

LUMislim Compounded Tirzepatide is a compounded preparation prepared by a Philippine-licensed compounding pharmacy under a physician order specific to your treatment. It is not a Philippine FDA-registered branded product; it is a physician-ordered compounded preparation dispensed per DOH AO 2020-0001 (telehealth provider model). If you prefer the branded option, LUMislim Mounjaro® (Eli Lilly's branded tirzepatide, US FDA-approved) is available from ₱13,499 — your physician will help you decide which option suits your assessment, budget, and medical history. Use only under continuous physician supervision. Not for use during pregnancy, breastfeeding, in patients under 18, or with active pancreatitis or thyroid C-cell disease. Store refrigerated; do not freeze. Do not share your medication with anyone.